Growth Hormone Deficiency (GHD)
Conditions
Brief summary
Final Height in Standard Deviation Score (FH SDS)
Detailed description
Growth Related: The proportion of children reaching normal adult height (- 2SD) The proportion reaching mid-parental Target Height (- 2SD) Difference in child's Target Height minus Final Height (in Standard Deviation Score and centimetres) Bone Related: Bone age delay at Final Height Bone age acceleration between enrolment and Final Height Bone health index at Final Height Biochemistry: Serum IGF-1 and lipid profiles (fasting lipids - serum triglyceride and total serum cholesterol) at Final Heig
Interventions
DRUGNutropinAq 10 mg/2 ml (30 IU) solution for injection.
DRUGSaizen 8 mg/ml Injektionslösung in einer Patrone
DRUGOmnitrope 5 mg/1.5 ml solution for injection in cartridge
DRUGHUMATROPE 6 mg - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
DRUGNorditropin FlexPro 15 mg/1
DRUG5 ml Injektionslösung in einem Fertigpen
DRUGGenotropin® MiniQuick 0
DRUG2 mg - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
Sponsors
University College London
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Final Height in Standard Deviation Score (FH SDS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Growth Related: The proportion of children reaching normal adult height (- 2SD) The proportion reaching mid-parental Target Height (- 2SD) Difference in child's Target Height minus Final Height (in Standard Deviation Score and centimetres) Bone Related: Bone age delay at Final Height Bone age acceleration between enrolment and Final Height Bone health index at Final Height Biochemistry: Serum IGF-1 and lipid profiles (fasting lipids - serum triglyceride and total serum cholesterol) at Final Heig | — |
Countries
Austria
Outcome results
None listed